



Contact:

Laura Comer
University General Hospital
713-652-3800
lcomer@uhsys.net
www.universitygeneralhospital.com

FOR IMMEDIATE RELEASE

University General Hospital Offers Innovative New Treatment for Blood Clots

Early Clot Treatment for Leg Veins Said to Improve Patient Outcomes

Houston, Texas, October 23, 2007. University General Hospital is now among cutting-edge institutions in the country offering an advanced treatment for patients suffering from deep vein thrombosis (DVT).

DVT is a common but serious medical condition that occurs in approximately two million Americans yearly. DVT occurs when a thrombus (blood clot) forms in large veins, usually in the legs, leading to either partially or completely blocked circulation. The condition may result in serious health complications such as a pulmonary embolism (PE) and even death if not diagnosed and treated effectively, according to the Coalition to Prevent Deep Vein Thrombosis.¹

The new treatment uses the FDA-cleared **Trellis[®] Peripheral Infusion System** from Bacchus Vascular, Inc., of Santa Clara, CA, to increase the efficiency of thrombolytic or “clot-busting” drugs in mixing with and removing blood clots. The system is also designed to reduce the risk of bleeding complications that are often associated with the use of thrombolytic drugs.

Using a technique known as “pharmaco-mechanical” thrombolysis, the Trellis system allows physicians at University General Hospital to provide rapid, effective and safe treatment for many patients suffering from acute DVT. This minimally invasive, interventional treatment modality is used in conjunction with the anti-coagulation drug regimen which is part of standard care for these patients.

Leading the effort at University General Hospital is David Shin, M.D., vascular surgeon and director of surgery for the hospital. Dr. Shin noted, “this new innovative approach to treating acute deep venous thrombosis will provide effective and immediate improvement in our patient’s symptoms and help prevent the long term debilitating complications resulting from deep venous thrombosis known as “post-phlebitic syndrome.”

National consensus standards for prevention and care of venous thromboembolism (VTE) are being studied by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO). Additionally, the American College of Chest Physicians (ACCP) is expected to issue a statement regarding early intervention of acute DVT. Commenting for University General Hospital, Sharon McDonough, chief operating officer, said, “At University General patient outcomes are our highest priority. This new treatment improves patient outcomes by reducing the risk of fatal pulmonary embolism and further blood clot formation in patients with DVT. “

Trellis is a registered trademark of Bacchus Vascular, Inc.

About University General Hospital. University General Hospital - Houston Fannin location, is a 72-bed licensed general acute care facility built on the principles of clinical excellence and five-star service. Further information about University General Hospital – may be found online at www.universitygeneralhospital.com.

About Bacchus Vascular. Bacchus Vascular, Inc. is a venture-backed medical device company dedicated to the treatment of occlusive vascular disease. www.bacchus-vascular.com.

References:

1 - <https://www.preventdvt.org/aboutDvt.aspx>